Bcl-2 antagonists, such as venetoclax, have shown in a recent phase II clinical trial in refractory CLL an incidence of pneumonia in 6% and febrile neutropenia in 5% of patients (83). Here, BCL2 is linked to susceptibility to pneumonia measurement.